H藥一線治療SCLC臨牀研究亮相頂級醫學期刊,復宏漢霖加速Biopharma進程
格隆匯9月28日丨2022年9月27日,由吉林省腫瘤醫院程穎教授牽頭的國際多中心研究——ASTRUM-005研究在全球四大頂級醫學期刊之一的《美國醫學會雜誌》(JAMA,影響因子:157.3)在線發表,成為全球首個登上JAMA主刊的小細胞肺癌免疫治療臨牀研究。ASTRUM-005研究是復宏漢霖自主研發的抗PD-1單抗H藥 漢斯狀®(斯魯利單抗)聯合化療一線治療廣泛期小細胞肺癌(ES-SCLC)的Ⅲ期臨牀研究,2022年ASCO年會程穎教授首次報吿結果後,引起了全球同行的廣泛關注,而今再度登上國際頂級學術舞台,體現了國際學術界的高度認可,彰顯出中國研究者的智慧化和生物醫藥領域國際一流的自主創新實力和臨牀運營能力。ASTRUM-005研究中斯魯利單抗聯合化療OS結果達15.4個月,刷新一線小細胞肺癌總生存期紀錄,與化療相比可以延長4.5個月的生存。目前全球尚無一線治療SCLC的抗PD-1單抗獲批,H藥有望成為全球首個一線治療SCLC的抗PD-1單抗,填補未來五年PD-1抑制劑一線治療小細胞肺癌的臨牀空白。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.